Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

Biomarkers For Enhanced Vaccine Safety

Cel

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveillance. A compact interlocking structure provides efficient and cost-effective goal delivery, while offering the full spectrum of functionality and capacity to match the needs for predictive biomarkers and models of inflammation/autoimmunity and clinical events classification. A Technology Core has transcriptomics, genotyping, proteomics, metabolomics and data mining, with depth and capacity to discover, validate and distribute novel biomarkers. A Models Core has a full range of ex vivo/in vivo murine, small animal and non-human primate models of inflammation and biomarker discovery, with advanced immunology and imaging. A Clinical Core has capability to safely and efficiently distribute clinical studies of vaccine immunosafety from small intensive trials to large-scale studies of adult, paediatric and other populations. A Populations Core has population-scale biobank discovery, clinical cohorts (with globalisation capability, autoimmune, chronic, inflammatory and infectious disease groups), large-scale genotyping and sequencing, and a safely accessible central database for online analyses of large datasets. A Regulatory Core with expertise to synthesise outputs to generate and disseminate classifications, guidelines, reference standards for vaccine development, and inform EFPIA activities. A Management Core with track record of successful public-private projects ensures Cores interoperate to maximise discovery - validation - application - re-discovery cycles, to deliver project goals on time, within budget, while maximising interactions with other actors (EFPIA, FDA, EMA).

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

IMI-JU-03-2010
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Koordynator

GLAXOSMITHKLINE VACCINES SRL
Wkład UE
Brak danych
Adres
VIA FIORENTINA 1
53100 SIENA
Włochy

Zobacz na mapie
Region
Centro (IT) Toscana Siena
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Francesco Gulli (Dr)
Kierownik naukowy
Giuseppe Del Giudice (Dr)
Linki
Koszt całkowity
Brak danych

Uczestnicy (21)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 10 Lutego 2022

Moja broszura

Permalink: https://cordis.europa.eu/project/id/115308/pl

European Union, 2024